By George Ulmann - Reporter, MedShr
More than 30,000 cardiovascular specialists attended Paris over five days to discuss the entire spectrum of cardiovascular medicine. The spotlight this year was on Global Cardiovascular Health, as ESC partnered with the World Heart Federation (WHF). A key highlight of the conference was the six Hot Line sessions, which attracted large crowds and showcased 28 trials.
Some of our highlights from ESC 2019:
DAPA-HF hot line trial results showed Dapaglifozin reduced worsening heart failure and cardiovascular deaths in patients with HFrEF both with and without diabetes
COMPLETE study showed that complete revascularisation reduces cardiovascular events compared to culprit-lesion only PCI in patients with STEMI and multivessel coronary artery disease
Prasugrel shown to reduce cardiovascular events in ACS patients compared to Ticagrelor in the ISAR-REACT5 trial
Notable unmet needs addressed in other landmark studies such as THEMIS and PARAGON HF.
Collaboration with the World Heart Federation (WHF) this year, as cardiovascular disease was highlighted as the number one worldwide killer, particularly in Western Europe, where the rate of premature cardiovascular death is increasing.
Worldwide mainstream media featured several other studies including:
Twice yearly jab has the potential to reduce bad cholesterol
Eating nuts linked with lower risk of fatal heart attack and stroke
Lifestyle, not genetics, explains most premature heart disease
Come and check out some of the great cases shared during the course in the MedShr ESC Group.